Avalo Therapeutics - AVTX Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVTX shares.
View AVTX analyst ratings or view top-rated stocks.

1 brokers have issued 1 year target prices for Avalo Therapeutics' shares. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 737.8% from the stock's current price.
View analysts price targets for AVTX or view top-rated stocks among Wall Street analysts.

Avalo Therapeutics' stock was trading at $5.0401 on January 1st, 2023. Since then, AVTX stock has decreased by 63.3% and is now trading at $1.85.
View the best growth stocks for 2023 here.

Avalo Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 24,800 shares, an increase of 30.5% from the February 13th total of 19,000 shares. Based on an average daily volume of 15,400 shares, the short-interest ratio is currently 1.6 days. Currently, 0.4% of the shares of the company are sold short.
View Avalo Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AVTX earnings forecast.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its earnings results on Wednesday, March, 2nd. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.12. Avalo Therapeutics had a negative net margin of 293.77% and a negative trailing twelve-month return on equity of 950.78%.

Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Avalo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (5.75%), Millennium Management LLC (0.46%), Susquehanna International Group LLP (0.20%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends.

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVTX stock can currently be purchased for approximately $1.85.

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $17.41 million and generates $5.40 million in revenue each year.

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.